Rubius Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2018

Rubius Therapeutics is a biotechnology company focused on developing innovative cellular therapies by transforming red blood cells into medicines. The company primarily serves patients with cancer and autoimmune diseases, aiming to provide life-changing treatments. Operating in the biopharmaceutical market, Rubius Therapeutics leverages its deep scientific expertise and dedicated team to advance its pipeline of promising drug candidates. The business model revolves around the research, development, and commercialization of these cellular therapies. Revenue is generated through the successful development and sale of these therapies, as well as potential partnerships and collaborations with other pharmaceutical companies. Keywords: cellular therapies, red blood cells, cancer treatment, autoimmune diseases, biotechnology, biopharmaceutical, drug development, clinical trials, innovative medicine, scientific expertise.

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

3 investors on Rubius Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Flagship Pioneering

Series B+ 2 investors entered at this stage

Massachusetts Institute of Technology

Whitehead Institute

Global footprint

Where Rubius Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States87.5%

🇦🇪 United Arab Emirates12.5%

2 countries shown

Web traffic by country

980 monthly visits
across markets

🇺🇸 United States102%

Top 1 markets shown

Talent graph

The shape of Rubius Therapeutics's talent

Dealroom maps Rubius Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

22 team members profilednamed & role-tagged by Dealroom

18 employeestotal headcount

4 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Rubius Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$1M patent portfolio · 11 active families

Estimated portfolio value

$1M

165.6× smaller than top peer Moderna Therapeutics ($189M)

11 active patent families

Where Rubius Therapeutics innovates BiochemistryBiophysicsCancer researchCarcinosisCell

Where Rubius Therapeutics concentrates vs peers

Each axis is a top-10 topic across Rubius Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Rubius Therapeutics

An AI-synthesized read of the highest-engagement posts about Rubius Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rubius Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles